1. Home
  2. IBRX vs TR Comparison

IBRX vs TR Comparison

Compare IBRX & TR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • TR
  • Stock Information
  • Founded
  • IBRX 2014
  • TR 1896
  • Country
  • IBRX United States
  • TR United States
  • Employees
  • IBRX N/A
  • TR N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • TR Specialty Foods
  • Sector
  • IBRX Health Care
  • TR Consumer Staples
  • Exchange
  • IBRX Nasdaq
  • TR Nasdaq
  • Market Cap
  • IBRX 2.3B
  • TR 2.5B
  • IPO Year
  • IBRX N/A
  • TR N/A
  • Fundamental
  • Price
  • IBRX $2.81
  • TR $34.97
  • Analyst Decision
  • IBRX Strong Buy
  • TR
  • Analyst Count
  • IBRX 5
  • TR 0
  • Target Price
  • IBRX $11.40
  • TR N/A
  • AVG Volume (30 Days)
  • IBRX 7.3M
  • TR 334.9K
  • Earning Date
  • IBRX 08-11-2025
  • TR 08-07-2025
  • Dividend Yield
  • IBRX N/A
  • TR 1.03%
  • EPS Growth
  • IBRX N/A
  • TR N/A
  • EPS
  • IBRX N/A
  • TR 1.21
  • Revenue
  • IBRX $31,222,000.00
  • TR $718,497,000.00
  • Revenue This Year
  • IBRX $567.98
  • TR N/A
  • Revenue Next Year
  • IBRX $160.56
  • TR N/A
  • P/E Ratio
  • IBRX N/A
  • TR $28.63
  • Revenue Growth
  • IBRX 10238.41
  • TR N/A
  • 52 Week Low
  • IBRX $1.83
  • TR $26.78
  • 52 Week High
  • IBRX $7.48
  • TR $36.25
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 51.33
  • TR 55.53
  • Support Level
  • IBRX $2.68
  • TR $33.67
  • Resistance Level
  • IBRX $3.00
  • TR $35.71
  • Average True Range (ATR)
  • IBRX 0.16
  • TR 0.91
  • MACD
  • IBRX -0.00
  • TR 0.04
  • Stochastic Oscillator
  • IBRX 62.00
  • TR 72.30

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About TR Tootsie Roll Industries Inc.

Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.

Share on Social Networks: